Ildong Pharmaceutical Co., Ltd. (KRX:249420)
South Korea
· Delayed Price · Currency is KRW 11,040
+20 (0.18%)
At close: Mar 24, 2025, 3:30 PM KST
Ildong Pharmaceutical Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2016 |
| Operating Revenue | 614,941 | 600,758 | 637,714 | 560,132 | 561,845 | Upgrade
|
| Other Revenue | - | -0 | - | -0 | - | Upgrade
|
| Revenue | 614,941 | 600,758 | 637,714 | 560,132 | 561,845 | Upgrade
|
| Revenue Growth (YoY) | 2.36% | -5.79% | 13.85% | -0.30% | 8.58% | Upgrade
|
| Cost of Revenue | 381,659 | 387,093 | 401,627 | 340,958 | 323,674 | Upgrade
|
| Gross Profit | 233,282 | 213,665 | 236,088 | 219,174 | 238,171 | Upgrade
|
| Selling, General & Admin | 167,539 | 165,116 | 190,252 | 171,296 | 164,598 | Upgrade
|
| Research & Development | 46,268 | 95,018 | 109,895 | 96,524 | 60,181 | Upgrade
|
| Other Operating Expenses | 1,262 | 1,216 | 3,814 | 1,087 | 1,454 | Upgrade
|
| Operating Expenses | 221,851 | 267,082 | 309,754 | 273,586 | 232,642 | Upgrade
|
| Operating Income | 11,431 | -53,418 | -73,666 | -54,412 | 5,529 | Upgrade
|
| Interest Expense | -15,938 | -14,725 | -9,788 | -10,556 | -4,669 | Upgrade
|
| Interest & Investment Income | 1,126 | 1,093 | 1,552 | 569.37 | 260.18 | Upgrade
|
| Earnings From Equity Investments | -273.49 | -0.36 | -0.54 | -1.67 | - | Upgrade
|
| Currency Exchange Gain (Loss) | -1,016 | -748.46 | -475.09 | 168.49 | -771.47 | Upgrade
|
| Other Non Operating Income (Expenses) | 6,790 | -24,556 | -20,485 | -75,458 | 1,049 | Upgrade
|
| EBT Excluding Unusual Items | 2,119 | -92,354 | -102,862 | -139,690 | 1,397 | Upgrade
|
| Gain (Loss) on Sale of Investments | 1,955 | 439.72 | 2,325 | -862.82 | -5,222 | Upgrade
|
| Gain (Loss) on Sale of Assets | -4,908 | 1,133 | -282.22 | -101.53 | 2,029 | Upgrade
|
| Asset Writedown | -9,857 | -3,492 | -19,004 | -550.27 | -7,928 | Upgrade
|
| Pretax Income | -10,692 | -94,273 | -119,823 | -141,205 | -9,724 | Upgrade
|
| Income Tax Expense | 1,710 | -13,312 | 22,346 | -40,237 | 3,295 | Upgrade
|
| Earnings From Continuing Operations | -12,402 | -80,961 | -142,170 | -100,968 | -13,019 | Upgrade
|
| Minority Interest in Earnings | 7,825 | 2,033 | 584.6 | 1,263 | - | Upgrade
|
| Net Income | -4,576 | -78,928 | -141,585 | -99,705 | -13,019 | Upgrade
|
| Net Income to Common | -4,576 | -78,928 | -141,585 | -99,705 | -13,019 | Upgrade
|
| Shares Outstanding (Basic) | 28 | 27 | 26 | 24 | 24 | Upgrade
|
| Shares Outstanding (Diluted) | 28 | 27 | 26 | 24 | 24 | Upgrade
|
| Shares Change (YoY) | 3.23% | 2.61% | 10.76% | -0.00% | -0.02% | Upgrade
|
| EPS (Basic) | -164.00 | -2920.00 | -5374.53 | -4191.88 | -547.34 | Upgrade
|
| EPS (Diluted) | -164.00 | -2920.00 | -5379.82 | -4192.00 | -547.34 | Upgrade
|
| Free Cash Flow | 17,614 | -49,817 | -65,413 | -25,992 | 5,014 | Upgrade
|
| Free Cash Flow Per Share | 631.25 | -1843.01 | -2483.08 | -1092.76 | 210.79 | Upgrade
|
| Gross Margin | 37.94% | 35.57% | 37.02% | 39.13% | 42.39% | Upgrade
|
| Operating Margin | 1.86% | -8.89% | -11.55% | -9.71% | 0.98% | Upgrade
|
| Profit Margin | -0.74% | -13.14% | -22.20% | -17.80% | -2.32% | Upgrade
|
| Free Cash Flow Margin | 2.86% | -8.29% | -10.26% | -4.64% | 0.89% | Upgrade
|
| EBITDA | 37,366 | -25,099 | -44,121 | -25,101 | 33,192 | Upgrade
|
| EBITDA Margin | 6.08% | -4.18% | -6.92% | -4.48% | 5.91% | Upgrade
|
| D&A For EBITDA | 25,935 | 28,319 | 29,545 | 29,311 | 27,663 | Upgrade
|
| EBIT | 11,431 | -53,418 | -73,666 | -54,412 | 5,529 | Upgrade
|
| EBIT Margin | 1.86% | -8.89% | -11.55% | -9.71% | 0.98% | Upgrade
|
| Advertising Expenses | 32,053 | 25,846 | 37,392 | 35,757 | 35,659 | Upgrade
|
Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.